FACILITIES AND SERVICE AGREEMENTFacilities and Service Agreement • May 1st, 2015 • Adaptimmune Therapeutics PLC • Biological products, (no disgnostic substances) • England and Wales
Confidential Treatment Requested under 17 C.F.R. Sections 200.80(b)(4) and 230.406 andAssignment and Exclusive Licence • May 1st, 2015 • Adaptimmune Therapeutics PLC • Biological products, (no disgnostic substances) • England and Wales
SUB-LICENSE AGREEMENT Between ADAPTIMMUNE LIMITED (as licensee) And LIFE TECHNOLOGIES CORPORATION (as licensor)Sub-License Agreement • May 1st, 2015 • Adaptimmune Therapeutics PLC • Biological products, (no disgnostic substances)
This Exclusive License (hereinafter called “LICENSE”) is made and entered into by and among the United States Department of the Navy at the Naval Medical Research Center (hereinafter called “NAVY”), the Regents of the University of Michigan (hereinafter called “UM”), Dana Farber Cancer Institute, Inc. (hereinafter call “DFCI”) and Invitrogen Corporation, a Delaware corporation (hereinafter called “LICENSEE”) whose headquarters are located at 5791 Van Allen Way, Carlsbad, CA 92008. Each of NAVY, UM, DFCI and LICENSEE is a “PARTY” hereunder, and may be collectively referred to as the “PARTIES”. Each of the NAVY, UM and DFCI is a LICENSOR hereunder, and may be collectively referred to as the LICENSORS.
